DUPIlumab Dose REDUCtion in Patients With Controlled Atopic Eczema
DUPIlumab Dose REDUCtion in Patients With Controlled Atopic Eczema
Recruiting · NCT06004986 · Registry updated 2025-10-08Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| DUPIlumab Dose REDUCtion in Patients With Controlled Atopic Eczema | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hypersensitivity, Immediate, Skin Diseases, Eczematous, Skin and Connective Tissue Diseases, atopic eczema, dermatitis, hereditary disease, hereditary skin disorder, immune system disorder, skin disorder | Recruiting | Phase 4 | 2025-10-08 | NCT06004986 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 199 |
| Erasmus Medical Center | 271 |
| Prothya Biosolutions | 3 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Amsterdam University Medical Centers | Amsterdam | Netherlands | 1 |
| Erasmus Medical Center | Rotterdam | Netherlands | 27 |